Replies to post #219902 on $Pistol Pete$, $Mick$ & Friends Stock Picks /news,

[mick]

$ABUS not bad good as read cash cow !!!!! Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
Zacks
Zacks Equity Research
ZacksAugust 7, 2020

https://finance.yahoo.com/news/arbutus-biopharma-abus-reports-q2-125512752.html

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.46 per share a year ago.

These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -8.70%.

A quarter ago, it was expected that this biopharmaceutical company
would post a loss of $0.32 per share when it actually produced a
loss of $0.25, delivering a surprise of 21.88%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Arbutus, which belongs to the Zacks Medical
- Biomedical and Genetics industry, posted revenues of $1.51 million for the quarter ended June 2020,
missing the Zacks Consensus Estimate by 17.94%.

This compares to year-ago revenues of $0.70 million.

The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock's immediate price movement based on
the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Arbutus shares have added about 57.2% since the beginning of the year versus the S&P 500's gain of 3.7%.

What's Next for Arbutus?

While Arbutus has outperformed the market so far this year,
the question that comes to investors' minds is:
what's next for the stock?

There are no easy answers to this key question,
but one reliable measure that can help investors address this is the company's earnings outlook.

Not only does this include current consensus earnings expectations
for the coming quarter(s),
but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.

Investors can track such revisions by themselves or rely on a
tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings
estimate revisions.

Ahead of this earnings release, the estimate revisions trend for
Arbutus was favorable.

While the magnitude and direction of estimate revisions could change following the company's just-released earnings report,

the current status translates into a Zacks Rank #2 (Buy) for the stock.

So, the shares are expected to outperform the market in the near future.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters
and current fiscal year change in the days ahead.

The current consensus EPS estimate is -$0.22 on $1.80 million in revenues for the coming quarter and -$0.87 on $7.32 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock
as well. In terms of the Zacks Industry Rank, Medical

- Biomedical and Genetics is currently in the top 48% of the 250 plus Zacks industries.

Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

[mick]

$ABUS 52-Wk Range 0.8214 - 9.02 Low High

[mick]

$ABUS Vaccines with Arbutus’ intellectual property,

their LNPs,

are already in Phase 2/3 trials & will be given
EUA (emergency use approval) before the end of the year, maybe sooner.

EARNINGS REPORT confirmed their stake in Genevant and their royalty T.B.A
SOON.


$ABUS SOON TO Receiving Royalties from the Sale of 100’s of Millions, POSSIIBLE Billions of Vaccines.